HB86 Alabama 2016 Session

This bill would prohibit a state regulated health benefit plan that covers intravenously administered, or injected anticancer therapies and orally administered anticancer therapies from requiring the insured to pay a higher copayment, deductible, or coinsurance amount for a patient-administered anticancer medication than is required for an anticancer medication that is injected or otherwise administered intravenously by a health care provider, regardless of the formulation or benefit category determination of the medication in the health benefit plan

This bill would also prohibit a health insurance plan from circumventing this prohibition by increasing the copayment, deductible, or coinsurance amount for an intravenous or injected chemotherapy drug that is covered under the health insurance plan or by reclassifying the anticancer benefits under the plan

Relating to insurance; to prohibit a state regulated health benefit plan that covers intravenously administered, or injected anticancer therapies and orally administered anticancer therapies from requiring the insured to pay a higher copayment, deductible, or coinsurance amount for an anticancer medication that is patient-administered than is required for an anticancer medication that is injected or otherwise administered intravenously by a health care provider, regardless of the formulation or benefit category determination of the medication in the health benefit plan; and to prohibit a health insurance plan from circumventing this prohibition by increasing the copayment, deductible, or coinsurance amount for an intravenous or injected chemotherapy drug that is covered under the health insurance plan or by reclassifying the anticancer benefits under the plan.